CYP2C9 and hepatocellular carcinoma: Furthermore, HCC patients with higher APEX1, ME1, S100A10 and ACACA expression or lower ADH1C and CYP2C9(p < 0.05) expression had poorer prognosis (Fig. 2D–I).